Search

ABSTRACTIntroduction: Breast cancer stands the second prominent cause of death among women. For its efficient treatment, Lapatinib (LAPA) was developed as a selective tyrosine kinase inhibitor of receptors, overexpressed by breast cancer cells. Various explored delivery strategies for LAPA indicated its controlled release with enhanced aqueous solubility, improved bioavailability, decreased plasma protein binding, reduced dose and toxicity to the other organs with maximized clinical efficacy, compared to its marketed tablet formulation.Areas covered: This comprehensive review deals with the survey, performed through different electronic databases, regarding various challenges and their solutions attained by fabricating delivery systems like nanoparticles, micelle, nanocapsules, nanochannels, and liposomes. It also covers the synthesis of novel LAPA-conjugates for diagnostic purpose.Expert opinion: Unfortunately, clinical use of LAPA is restricted because of its extensive albumin binding capacity, poor oral bioavailability, and poor aqueous solubility. LAPA is marketed as the oral tablet only. Therefore, it becomes imperative to formulate alternate efficient multiparticulate or nano-delivery systems for administration through non-oral routes, for active/passive targeting, and to scale-up by pharmaceutical scientists followed by their clinical trials by clinical experts. LAPA combinations with capecitabine and letrozole should also be tried for breast cancer treatment.

In the current research work, losartan potassium (LP) loaded Self Emulsifying Drug Delivery System (SEDDS) was formulated using various ratios of lipids, surfactants and co-surfactants to prevent its first pass metabolism. A pseudo-ternary phase diagram was plotted to establish the emulsification region. Total of eight batches (F1 to F8) were prepared and subjected to different characterizations (thermodynamic study, phase separation, zeta potential and particle size) studies to obtain the optimized formulation. The optimized SEDDS (F8) with 40% oil, 60% surfactant and co-surfactant mixture (Smix) (6:1 ratio) was found to be a thermodynamically stable emulsion, with droplet size at around 204.7 ± 5.0 nm, surface charge −13.38 ± 1.5 mV and polydispersity index 0.221 ± 0.03. The SEM study confirmed the spherical shape and even surface of the droplets. The In-vitrodrug release profile of optimized formulation exhibited a similar rate and extent of dissolution as compared to the marketed formulation. Further, the optimized formulation had shown equivalent therapeutic efficacy (anti-hypertensive) with respect to the marketed tablet at half of the dose of the drug in SEDDS formulation.